Policy & Regulation
Graybug Vision starts phase 2a study with GB-102
20 September 2019 -

Graybug Vision, a clinical stage pharmaceutical company, has started its phase 2a study with GB-102 in patients with macular oedema derived from diabetic macular oedema or retinal vein occlusion, it was reported yesterday.

The product is a pan-Vascular Endothelial Growth Factor inhibitor and potential twice-per-year therapy aimed at decreasing the requirement for frequent intravitreal injections in retinal diseases. It aims to decrease the significant treatment burden and sub-optimal visual results experienced because of the difficulty in patients visiting the retinal specialist several times a year for required injections and eye examinations.

The GB-102 Phase 2a open label, six-month study hopes to prove the safety of GB-102 and evidence of its durability. It will recruit 20 macular oedema patients at six centres in the US. They will be treated with a single intravitreal injection of 1mg or 2mg of GB-102, Graybug Vision's microparticle depot formulation of sunitinib malate.

Login
Username:

Password: